Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(4): 319-332, 2023 01 26.
Artigo
Inglês
| MEDLINE | ID: mdl-36511784
2.
Is Short-Course Antibiotic Therapy Suitable for Pseudomonas aeruginosa Bloodstream Infections in Onco-hematology Patients With Febrile Neutropenia? Results of a Multi-institutional Analysis.
Clin Infect Dis
; 78(3): 518-525, 2024 03 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37795577
3.
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.
Cancer
; 130(3): 421-432, 2024 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37846845
4.
Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.
Haematologica
; 109(2): 591-603, 2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37534514
5.
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
Haematologica
; 2024 Jan 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38235512
6.
Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM).
Ann Hematol
; 103(4): 1305-1315, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38049586
7.
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 99(4): 523-533, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38247315
8.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol
; 20(12): 717-726, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38088119
9.
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE.
Int J Cancer
; 153(5): 1016-1025, 2023 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37204683
10.
Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase.
Br J Haematol
; 201(4): 704-717, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36755409
11.
Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
Br J Haematol
; 202(3): 517-524, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37192741
12.
A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Blood
; 137(21): 2890-2901, 2021 05 27.
Artigo
Inglês
| MEDLINE | ID: mdl-33512480
13.
Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation.
Ann Hematol
; 102(11): 3195-3204, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37679605
14.
A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies.
Br J Haematol
; 198(1): 62-72, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35383885
15.
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
BMC Med
; 20(1): 108, 2022 04 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35379237
16.
Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia.
J Transl Med
; 20(1): 576, 2022 12 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36494694
17.
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.
Blood
; 136(4): 468-479, 2020 07 23.
Artigo
Inglês
| MEDLINE | ID: mdl-32187357
18.
Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).
Ann Hematol
; 101(12): 2679-2690, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36301338
19.
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
Ann Hematol
; 101(6): 1201-1210, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-35437610
20.
Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
Br J Haematol
; 194(5): 862-869, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34328213